Collaborative Expansion IBEX has recently entered a collaboration with Sus Clinicals, Inc. to accelerate oncologic innovations in preclinical surgical studies, signaling openness to strategic partnerships that could broaden service offerings and access to genetically-modified large animal models.

Diversified Capabilities With expertise spanning orthopedics, wound care, ophthalmology, cardiovascular, gastrointestinal, implant toxicity, and non-surgical toxicology and pharmacokinetic studies, IBEX can position as a one-stop preclinical partner for medical device companies seeking comprehensive safety and efficacy testing.

Quality and Compliance As an AAALAC accredited and GLP compliant facility guided by experienced veterinary surgeons and research staff, IBEX can target clients requiring high GRP/GLP standards, appealing to mid to large-cap medtech firms prioritizing quality assurance.

Strategic Acquisitions The 2022 acquisition history and private investment backing indicate a growth mindset and potential for scaled operations; this can attract clients seeking robust capabilities and continuity in testing as they expand their product portfolios.

Tech Enablement IBEX leverages a modern tech stack including AWS, Open Graph, WordPress, Shopify, and collaboration tools, which can be marketed as enabling efficient study lifecycle management, client portals, and transparent data delivery to accelerate sales cycles.